Simultaneous rectal neuroendocrine tumors and pituitary adenoma: A case report and review of literature

Esophageal cancer (EC) ranks among the most prevalent malignant tumors affecting the digestive tract. Esophageal squamous cell carcinoma (ESCC) stands as the prevailing pathological subtype, encompassing approximately 90% of all EC patients. In clinical stage II-IVA locally advanced ESCC cases, the primary approach to treatment involves a combination of neoadjuvant therapy and surgical resection. Despite concerted efforts, the long-term outcomes for ESCC patients remain unsatisfactory, with dismal prognoses. However, recent years have witnessed remarkable strides in immunotherapy, particularly in the second- and first-line treatment of advanced or metastatic ESCC, with the development of monoclonal antibodies that inhibit programmed death 1 or programmed death ligand 1 demonstrating encouraging responses and perioperative clinical benefits for various malignancies, including ESCC. This comprehensive review aims to present the current landscape of perioperative immunotherapy for resectable ESCC, focusing specifically on the role of immune checkpoint inhibitors during the perioperative period. Additionally, the review will explore promising biomarkers and offer insights into future prospects.

[1]  L. Kasuki,et al.  Acromegaly and Colorectal Neoplasm: An Update , 2022, Frontiers in Endocrinology.

[2]  Ibrahim Sange,et al.  Acromegaly and the Colon: Scoping Beyond the Pituitary , 2021, Cureus.

[3]  K. Koeller,et al.  Primary Tumors of the Pituitary Gland: Radiologic-Pathologic Correlation. , 2021, Radiographics : a review publication of the Radiological Society of North America, Inc.

[4]  S. Cannavò,et al.  Global epidemiology of acromegaly: a systematic review and meta-analysis. , 2021, European journal of endocrinology.

[5]  G. Cassese,et al.  Diagnosis and Management of Rectal Neuroendocrine Tumors (NETs) , 2021, Diagnostics.

[6]  Yiwei Li,et al.  Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor , 2021, Frontiers in Oncology.

[7]  H. Werner,et al.  Role of the GH-IGF1 system in progression of cancer , 2020, Molecular and Cellular Endocrinology.

[8]  M. Manzoni,et al.  Update on gastroenteropancreatic neuroendocrine tumors. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  C. Dimopoulou,et al.  Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population? , 2020, European journal of endocrinology.

[10]  A. Beckers,et al.  The Epidemiology of Pituitary Adenomas. , 2020, Endocrinology and metabolism clinics of North America.

[11]  J. Hrabe.  Neuroendocrine Tumors of the Appendix, Colon, and Rectum. , 2020, Surgical oncology clinics of North America.

[12]  A. Grossman,et al.  Colonic Cancer and Acromegaly , 2019, Front. Endocrinol..

[13]  M. Zhou,et al.  Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms , 2019, Clinical nuclear medicine.

[14]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[15]  Salma M. AlDallal.  Acromegaly: a challenging condition to diagnose , 2018, International journal of general medicine.

[16]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[17]  Minhu Chen,et al.  Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China , 2017, Chinese journal of cancer.

[18]  N. Karavitaki,et al.  Epidemiology of acromegaly: review of population studies , 2016, Pituitary.

[19]  R. Lonser,et al.  Management of hormone-secreting pituitary adenomas , 2016, Neuro-oncology.

[20]  T. Gress,et al.  Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature , 2016, BMC Research Notes.

[21]  V. Steinthorsdottir,et al.  The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. , 2015, European journal of endocrinology.

[22]  L. Moilanen,et al.  Mortality in acromegaly: a 20-year follow-up study. , 2015, Endocrine-related cancer.

[23]  J. Ayuk,et al.  Treatment Factors That Influence Mortality in Acromegaly , 2015, Neuroendocrinology.

[24]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[25]  E. Holmberg,et al.  The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. , 2014, European journal of endocrinology.

[26]  M. Gadelha,et al.  Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. , 2013, Arquivos brasileiros de endocrinologia e metabologia.

[27]  W. Oyen,et al.  Optimized labeling of NOTA-conjugated octreotide with F-18 , 2011, Tumor Biology.

[28]  P. Jones,et al.  Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. , 2011, The Journal of clinical endocrinology and metabolism.

[29]  Manal M. Hassan,et al.  Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Thorax ( Includes Lung and Thymus ) , 2010 .

[30]  W. Oyen,et al.  A Novel Facile Method of Labeling Octreotide with 18F-Fluorine , 2010, Journal of Nuclear Medicine.

[31]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[32]  J. Vandenbroucke,et al.  Mortality in acromegaly: a metaanalysis. , 2008, The Journal of clinical endocrinology and metabolism.